Volume 6, Number 4Point-CounterpointThe Role of Serum Testosterone Testing: Routine Hormone Analysis Is an Essential Part of the Initial Screening of Men With Erectile DysfunctionJohn L GoreJacob RajferTestosteroneHypogonadismErectile dysfunction
Volume 6, Supplement 6SupplementDiagnosis of Hypogonadism: Clinical Assessments and Laboratory TestsChristina CarnegieTestosterone replacement therapyHypogonadismSerum hormone-bindingglobulinLuteinizing hormoneFollicle-stimulating hormone
Volume 6, Supplement 6SupplementEarly Response Time in Sexual Activity and Mood Following Testosterone Gel Replacement in Hypogonadal Males from the Testim START StudyMark J SwierzewskiCarol O'NeillJim GriesserEdward LoizidesTed SmithHypogonadismTestosterone gelMoodSexual function
Volume 6, Supplement 6SupplementLong-Term Effects of Testim 1% Testosterone Gel in Hypogonadal MenChristina CarnegieJohn RodzvillaTed SmithJohn D DeanHypogonadismTestosterone gelMoodSexual functionBone mineraldensityBody composition
Volume 6, Supplement 6SupplementOsteopenia and Male HypogonadismKendall DupreeAdrian DobsTestosteroneHypogonadismOsteoporosisBone mineral density
Volume 6, Supplement 6SupplementTreatment of Erectile Dysfunction in a Hypogonadal MaleJohn P MulhallHypogonadismErectile dysfunctionSildenafil citrate
Volume 7, Number 2Review ArticlesLong-Term Effects of Testim® 1% Testosterone Gel in Hypogonadal MenTed SmithChristina CarnegieJohn RodzvillaJohn D DeanHypogonadismTestosterone gelMoodSexual functionBone mineraldensityBody composition
Volume 12, Number 4Review ArticlesMetabolic Syndrome and Urologic DiseasesMangement ReviewIlya GorbachinskyHaluk AkpinarMetabolic syndrome (MetS) is a complex entity consisting of multiple interrelated factors including insulin resistance, central adiposity, dyslipidemia, endothelial dysfunction and atherosclerotic disease, low-grade inflammation, and in males, low testosterone levels. MetS has been linked to a number of urologic diseases including nephrolithiasis, benign prostatic hyperplasia and lower urinary tract symptoms, erectile dysfunction, male infertility, female incontinence, and prostate cancer. This article reviews the relationships between MetS and these entities. Urologists need to be cognizant of the impact that MetS has on urologic diseases as well as on overall patient health.[Rev Urol. 2010;12(4):e157-e180 doi: 10.3909/riu0487]© 2010 MedReviews®, LLCObesityMetabolic syndromeBenign prostatic hyperplasiaNephrolithiasisHypogonadismCardiovascular diseaseInsulin resistanceEndothelial dysfunction
Volume 16, Number 3Review ArticlesManagement of Erectile Dysfunction in the Hypogonadal Man: A Case-Based ReviewManagement ReviewLarry I LipshultzJason R KovacNathan A WilkenRanjith RamasamyJason M ScovellErectile dysfunction (ED) has emerged as an important marker of cardiovascular and overall health, independent of other known conventional risk factors. ED often precedes coronary artery disease in half of affected subjects, and could indicate the presence of cardiovascular pathology. The pathophysiology and role of androgens in sexual function are described, along with the relevant literature on the effects of aging in erectile and gonadal function. The concept of testosterone supplementation (TST) in men with ED is reviewed. The authors utilize clinical vignettes to discuss the appropriate management of two clinical cases of men at different life stages who have ED in the setting of hypogonadism and propose a treatment algorithm. In patients of all ages, proper identification of the underlying pathophysiology of decreased libido and erectile function is paramount in choosing between the use of TST, phosphodiesterase type 5 inhibitors, or both, in the management of these disorders. [Rev Urol. 2014;16(3):105-109 doi: 10.3909/riu0623] © 2014 MedReviews®, LLCHypogonadismErectile dysfunctionTestosterone supplementationPhosphodiesterase
Volume 18, Number 2Review ArticlesThe Role of Estrogen Modulators in Male Hypogonadism and InfertilityDisease State ReviewAmarnath RambhatlaJesse N MillsJacob RajferEstradiol, normally considered a female hormone, appears to play a significant role in men in a variety of physiologic functions, such as bone metabolism, cardiovascular health, and testicular function. As such, estradiol has been targeted by male reproductive and sexual medicine specialists to help treat conditions such as infertility and hypogonadism. The compounds that modulate estradiol levels in these clinical conditions are referred to as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). In a certain subset of infertile men, particularly those with hypogonadism, or those who have a low serum testosterone to estradiol ratio, there is some evidence suggesting that SERMs and AIs can reverse the low serum testosterone levels or the testosterone to estradiol imbalance and occasionally improve any associated infertile or subfertile state. This review focuses on the role these SERMs and AIs play in the aforementioned reproductive conditions. [Rev Urol. 2016;18(2):66-72 doi: 10.3909/riu0711] © 2016 MedReviews®, LLCSelective estrogen receptor modulatorAromatase inhibitorMale infertilityHypogonadism